Tamar D Howson
CIK 1202286 · EVP of Bus Dev · last filed 2026-06-29
Tamar D Howson is an EVP of Bus Dev who has filed 57 SEC Form 4 insider transactions across 10 companies since 2008. The most recent filing, for IMUX, was dated Jun 29, 2026. Across all open-market trades the lifetime net is +$9.8K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $71.9K across reported positions. 5 SEC filings were submitted jointly with Actavis plc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
OXGN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMUX | Director | — | $7.96 | — | $0 | 9 | 2026-06-29 |
| Lite Strategy, Inc. (MEIP) Delisted | Director | — | $3.20 | — | $0 | 5 | 2023-10-12 |
| CUE | Director | — | $20.14 | — | $0 | 4 | 2023-01-05 |
| VivoSim Labs, INC. (ONVO) Delisted | Director | 31 | $2.04 | $63 | $0 | 6 | 2018-07-30 |
| Hepion Pharmaceuticals, Inc. (CTRV) Delisted | Director | — | — | — | $0 | 1 | 2017-04-11 |
| Oncotelic Therapeutics, Inc. (OXGN) Delisted | Director | 8,761 | — | — | $9.8K | 13 | 2015-05-29 |
| ACT | Director | 1,539 | $46.71 | $71.9K | $0 | 1 | 2015-03-19 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Director | — | — | — | $0 | 7 | 2014-08-05 |
| ARADIGM CORP (ARDM) Delisted | Director | 3,308 | — | — | $0 | 3 | 2012-05-30 |
| LXRX | EVP of Bus Dev | — | $1.82 | — | $0 | 1 | 2008-02-11 |
Recent Filings
57 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-29 | IMUX | Grant (A) | — | $0 | EDGAR |
| 2025-06-09 | IMUX | Grant (A) | — | $0 | EDGAR |
| 2024-06-12 | IMUX | Grant (A) | — | $0 | EDGAR |
| 2024-03-06 | IMUX | Mixed | — | $0 | EDGAR |
| 2023-10-12 | Lite Strategy, Inc. (MEIP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-29 | IMUX | Grant (A) | — | $0 | EDGAR |
| 2023-01-05 | CUE | Grant (A) | — | $0 | EDGAR |
| 2022-07-07 | Lite Strategy, Inc. (MEIP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-17 | IMUX | Grant (A) | — | $0 | EDGAR |
| 2022-01-05 | CUE | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.